SymBio Pharmaceuticals Ltd represents values of innovation, collaboration, and patient-centric approach. With a strong corporate philosophy, the company focuses on developing novel therapies to address unmet medical needs. SymBio Pharmaceuticals Ltd believes in fostering strategic partnerships and actively engaging with key stakeholders to drive advancements in healthcare. Their commitment to scientific excellence and dedication to improving patients' lives fuel their mission to develop transformative treatments. As a forward-thinking pharmaceutical company, SymBio Pharmaceuticals Ltd prioritizes the health and well-being of individuals, guided by their core values and corporate philosophy.

SymBio Pharmaceuticals Ltd is primarily present in Japan. As a pharmaceutical company, SymBio focuses on developing and commercializing therapeutics for oncology and autoimmune diseases. Headquartered in Tokyo, Japan, the company has established a strong presence within its domestic market. SymBio Pharmaceuticals Ltd's innovative research and development efforts have led to the introduction of several important drugs in Japan. With a commitment to improving patient care and addressing unmet medical needs, SymBio Pharmaceuticals Ltd continues to expand its reach within the Japanese pharmaceutical industry.

SymBio Pharmaceuticals Ltd has achieved several significant milestones. In recent years, the company received approval for Treakisym, its flagship product which is used in the treatment of non-Hodgkin's lymphoma and other malignant lymphomas. SymBio Pharmaceuticals also successfully entered into licensing and collaboration agreements with renowned companies, expanding its global presence and creating opportunities for further growth. Moreover, the company received device approval for Cutisum, a new formulation of Treakisym, providing patients with an improved treatment option. These milestones demonstrate SymBio Pharmaceuticals' commitment to innovation and its dedication to advancing healthcare solutions for patients worldwide.

SymBio Pharmaceuticals Ltd was established in 2005 and is a biopharmaceutical company based in Japan. The company focuses on the development and commercialization of novel oncology therapeutics. With a strong commitment to research and development, SymBio Pharmaceuticals has successfully launched several products in the oncology field, including bendamustine hydrochloride, which is used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio Pharmaceuticals leverages its deep expertise in drug development and collaborations with global pharmaceutical companies to advance its pipeline of innovative therapies. The company is dedicated to making a meaningful impact in the healthcare industry by providing effective and safe treatment options for cancer patients.

The main competitors of SymBio Pharmaceuticals Ltd in the market are XYZ Pharmaceuticals and ABC Biotech.

SymBio Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of SymBio Pharmaceuticals Ltd is centered around the development and commercialization of innovative therapeutic drugs. Being a specialty pharmaceutical company, SymBio focuses on the research, clinical development, and distribution of pharmaceutical products, particularly in the field of oncology and autoimmune diseases. By leveraging its expertise in drug discovery and strategic partnerships, SymBio aims to bring novel and effective treatments to patients worldwide. With a commitment to addressing unmet medical needs, SymBio Pharmaceuticals Ltd strives to deliver high-quality and differentiated healthcare solutions to improve patients' lives.

Poměr SymBio Pharmaceuticals P/E je 4,67.

Koeficient SymBio Pharmaceuticals tržních hodnot je 0,74.

AlleAktien kvalitní skóre pro SymBio Pharmaceuticals je 3/10.

očekávané SymBio Pharmaceuticals obrat je 12,93 mld. JPY.

očekávané SymBio Pharmaceuticals zisk je 2,05 mld. JPY.

SymBio Pharmaceuticals Ltd is a leading, globally active company that focuses on the development, approval, and marketing of innovative pharmaceuticals. The company was founded in Japan in 2005 and now has numerous branches worldwide. The company's business strategy is aimed at providing patients worldwide with access to high-quality therapy options that improve medical practice and enhance patients' quality of life. The company relies on targeted research and development as well as close collaboration with academic institutions, other pharmaceutical companies, and patient groups. SymBio Pharmaceuticals operates in three business areas: Pharma Products, Licensing & Development, and Clinical Trials. Pharma Products: SymBio Pharmaceuticals currently offers four products, all of which are approved in Japan. The company has launched Nipent® (Pentostatin), a medication for the treatment of hairy cell leukemia. Ramucirumab (Cyramza®) and Ibritumomab (Zevalin®) are approved in Japan and used in the field of oncology. Treakisym® is a medication for non-Hodgkin lymphomas and is also marketed in Taiwan. The company is working on adding more products and indications to its portfolio. Licensing & Development: SymBio Pharmaceuticals has extensive experience in licensing active substances and technologies from around the world, as well as in collaborating with partners in drug development. The company offers its customers a wide range of services, from early research to drug approval. Clinical Trials: SymBio Pharmaceuticals has conducted a wide range of clinical trials and has extensive expertise in the field of clinical studies, from Phase I to Phase III. The company works closely with academic institutions, other pharmaceutical companies, and CROs to conduct clinical trials. In recent years, SymBio Pharmaceuticals has pursued a successful growth strategy and expanded its business through strategic partnerships and acquisitions. For example, in 2018, the company acquired a majority stake in a company that produces and markets specialized oncology products. In the same year, SymBio announced plans to establish a new cancer research institute in collaboration with other research institutions. Overall, SymBio Pharmaceuticals believes in the importance of innovation and collaboration to meet the medical needs of patients worldwide. The company remains actively seeking new partnerships and acquisition opportunities to continuously expand its product line and services.

SymBio Pharmaceuticals vyplácí dividendu ve výši 0 JPY rozdělenou do výplat během roku.

Dividenda pro SymBio Pharmaceuticals momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti SymBio Pharmaceuticals je JP3383050006.

WKN společnosti SymBio Pharmaceuticals je A1JMJE.

Ticker společnosti SymBio Pharmaceuticals je 4582.T.

Během posledních 12 měsíců vyplatila společnost SymBio Pharmaceuticals dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že SymBio Pharmaceuticals vyplatí dividendu ve výši 0 JPY.

Výnos z dividend společnosti SymBio Pharmaceuticals aktuálně činí .

SymBio Pharmaceuticals vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

SymBio Pharmaceuticals vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 JPY. To odpovídá dividendovému výnosu 0 %.

SymBio Pharmaceuticals je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě SymBio Pharmaceuticals ve výši 0 JPY, zaznamenané 29. 11. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 29. 11. 2024.

Poslední dividendy byly vyplaceny dne 29. 11. 2024.

V roce 2023 společností SymBio Pharmaceuticals bylo vyplaceno 0 JPY ve formě dividend.

Dividendy společnosti SymBio Pharmaceuticals jsou vypláceny v JPY.